Physician profile
Edwin Y Lin
NPI 1477755288
$3,202.50
in general payments reported to CMS, 2019-2025
40 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.83 · 2020: $13.34 · 2021: $76.29 · 2022: $159 · 2023: $21.99 · 2024: $1,322 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.92 |
| Education | $192.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $395.88 | 2024-2025 | |
| Pfizer INC. | $298.20 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $252.82 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $177.10 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $175.98 | 2022-2025 | Rybrevant, Tecvayli, Talvey |
| Astellas Pharma US INC | $148.98 | 2024 | |
| Beone Medicines USA, INC. | $131.47 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $115.45 | 2024-2025 | Calquence, Enhertu |
| Abbvie INC. | $98.10 | 2024-2025 | |
| Celgene Corporation | $92.60 | 2022-2025 | Reblozyl |
| Eisai INC. | $86.55 | 2023-2025 | |
| Puma Biotechnology, INC. | $77.75 | 2025 | |
| Daiichi Sankyo INC. | $76.92 | 2024-2025 | Enhertu, Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $76.19 | 2024-2025 | Ninlaro, Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $74.31 | 2022-2024 | Libtayo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $72.70 | 2024 | |
| Gilead Sciences, INC. | $69.80 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $68.14 | 2025 | Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $61.64 | 2024-2025 | Onivyde, Somatuline Depot |
| Geron Corporation | $54.00 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $52.90 | 2024-2025 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $49.32 | 2025 | |
| Deciphera Pharmaceuticals INC. | $41.47 | 2024-2025 | Qinlock, Romvimza |
| Glaxosmithkline, LLC. | $39.90 | 2024 | Jemperli, Zejula |
| Alexion Pharmaceuticals, INC. | $38.35 | 2025 | Ultomiris |
| Stemline Therapeutics INC. | $36.45 | 2025 | Orserdu |
| Exelixis INC. | $36.02 | 2024 | Cabometyx |
| Jazz Pharmaceuticals INC. | $35.32 | 2024 | |
| Genmab U.S., INC. | $34.12 | 2025 | Epkinly |
| Genentech USA, INC. | $32.31 | 2025 | Polivy |
| Karyopharm Therapeutics INC. | $29.48 | 2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $29.28 | 2025 | |
| Genzyme Corporation | $24.96 | 2025 | |
| Servier Pharmaceuticals LLC | $21.80 | 2024 | |
| Coherus Oncology, INC. | $21.44 | 2025 | Loqtorzi |
| Incyte Corporation | $21.06 | 2024 | Jakafi |
| Array Biopharma INC | $19.60 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.42 | 2025 | Empaveli |
| Medtronic, INC. | $15.72 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.